- Home
- DSM vs OABI Comparison
DSM vs OABI Comparison
Compare DSM & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSM
- OABI
- Stock Information
- Founded
- DSM 1989
- OABI 2012
- Country
- DSM United States
- OABI United States
- Employees
- DSM N/A
- OABI N/A
- Industry
- DSM Investment Managers
- OABI Biotechnology: Pharmaceutical Preparations
- Sector
- DSM Finance
- OABI Health Care
- Exchange
- DSM Nasdaq
- OABI Nasdaq
- Market Cap
- DSM 280.8M
- OABI 227.4M
- IPO Year
- DSM N/A
- OABI N/A
- Fundamental
- Price
- DSM $5.97
- OABI $1.75
- Analyst Decision
- DSM
- OABI Strong Buy
- Analyst Count
- DSM 0
- OABI 3
- Target Price
- DSM N/A
- OABI $6.67
- AVG Volume (30 Days)
- DSM 161.7K
- OABI 613.6K
- Earning Date
- DSM 01-01-0001
- OABI 11-11-2025
- Dividend Yield
- DSM 3.97%
- OABI N/A
- EPS Growth
- DSM N/A
- OABI N/A
- EPS
- DSM N/A
- OABI N/A
- Revenue
- DSM N/A
- OABI $23,027,000.00
- Revenue This Year
- DSM N/A
- OABI N/A
- Revenue Next Year
- DSM N/A
- OABI $48.74
- P/E Ratio
- DSM N/A
- OABI N/A
- Revenue Growth
- DSM N/A
- OABI 6.05
- 52 Week Low
- DSM $4.69
- OABI $1.22
- 52 Week High
- DSM $6.05
- OABI $4.87
- Technical
- Relative Strength Index (RSI)
- DSM N/A
- OABI 48.96
- Support Level
- DSM N/A
- OABI $1.58
- Resistance Level
- DSM N/A
- OABI $1.72
- Average True Range (ATR)
- DSM 0.00
- OABI 0.08
- MACD
- DSM 0.00
- OABI 0.02
- Stochastic Oscillator
- DSM 0.00
- OABI 59.29
About DSM BNY Mellon Strategic Municipal Bond Fund Inc.
BNY Mellon Strategic Municipal Bond Fund, Inc. is a diversified closed-end management investment company. Its investment objective is to seek to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital.
About OABI OmniAb Inc.
OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.